However due to the alloantigens of the recipient T cell therapy endogenous genes/housekeeping genes such as T cell receptor (TCR), and major histocompatibility complex genes (MHC) could lead to graft-versus-host-disease (GVHD) due to HLA-mismatching, which could prevent by CRISPR gene editing, inactivation (knocking out) of endogenous T cell receptor (TCR) genes [14, 27]. This evidence concerns the gene HLA-C and graft versus host disease.